Clinical Trials
14 trialsNCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02377999 2025-02-24
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
Phase 2 Completed
NCT03546166 2023-07-21
PICABAS
Centre Hospitalier Universitaire de Nice
Phase 2 Completed
NCT02354391 2019-03-26
Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis
Pacific Dermaesthetics
Phase 2 Unknown
NCT00375739 2016-01-28
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
Peplin
Phase 2 Completed
NCT00427050 2015-09-14
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT00544297 2015-04-02
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
Peplin
Phase 2 Completed
NCT00107965 2015-03-25
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Peplin
Phase 2 Completed
NCT00239135 2015-03-25
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT00852137 2015-03-06
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Peplin
Phase 2 Completed
NCT00108121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT00329121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
Peplin
Phase 2 Completed
NCT01214564 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Peplin
Phase 2 Completed
NCT00108134 2008-12-24
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Peplin
Phase 2 Completed